THOMAS A BUCHHOLZ to Antibodies, Monoclonal
This is a "connection" page, showing publications THOMAS A BUCHHOLZ has written about Antibodies, Monoclonal.
Connection Strength
0.118
-
Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer. 2010 Jul 01; 116(13):3084-92.
Score: 0.038
-
Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol. 2009 May; 33(5):759-67.
Score: 0.035
-
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 01; 13(1):228-33.
Score: 0.029
-
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011 Mar; 22(3):515-523.
Score: 0.009
-
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85.
Score: 0.006